11A-1070905
TW I 718526
The present disclosure provides a method for preventing and/or treating a cancer, comprising administering an active BIK (BIKDD) in combined with the blockage of BIKDD ubiquitination pathway in a subject. Also provided is a method for preventing and/or treating a cancer in a subject, comprising a combinatory treatment of BIK pathway followed by an administration of an IRE a inhibitor.
BIKDD gene therapy in combination with the targeting IRE1a/XBP1 pathway using IRE1a inhibitor, IRE1a shRNA or XBP1 shRNA as an anti-tumor strategy. Such combinations has the following advantage:
- Enhance tumor killing.
- Reduce the frequency of BIKDD treatment.
- Prolong half-life of BIKDD.
Preventing and/or treating cancer.
Ruey-Hwa Chen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Combined inhibition of IRE1 a pathway with BIKDD gene delivery as an anti-cancer strategy.